A Multi-Center, Open-Label, Single Ascending Dose Study To Assess the Safety, Tolerability, and Serum Pharmacokinetics of Intravitreal CLG561 in Subjects With Advanced Age-Related Macular Degeneration
Phase of Trial: Phase I
Latest Information Update: 29 Mar 2016
Price : $35 *
At a glance
- Drugs CLG 561 (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Sponsors Alcon
- 24 Mar 2016 no of cohorts changed from 4 (50micro lit) to 5 cohorts (4 cohorts each of 40micro lit + 1 cohort of 100micro lit) as per ClinicalTrials.gov record.
- 12 Nov 2014 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 12 Aug 2014 Planned End Date changed from 1 May 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov.